USAN Modifies Lead Drug Candidate’s Chemical Name to ‘Simufilam’
November 27 2020 - 8:30AM
Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the
World Health Organization (WHO) advised the United States Adopted
Names Council (USAN) to modify the chemical name of the Company’s
lead drug candidate to ‘simufilam.’ This change was advised by WHO
to avoid a potential trademark conflict with a drug marketed in the
Far East.
USAN has accepted WHO’s advice. Future
references to Cassava Sciences’ lead drug candidate for Alzheimer’s
disease will be simufilam.
About USANThe United States
Adopted Names Council is responsible for selecting simple,
informative and unique nonproprietary drug names. The USAN Council
establishes logical nomenclature classifications based on
pharmacological or chemical relationships. In addition to one
member-at-large and a U.S. Food and Drug Administration liaison,
USAN consists of one representative from The American Medical
Association, the United States Pharmacopeia and the American
Pharmacists Association.
About Alzheimer's
DiseaseAlzheimer’s disease is a progressive brain disorder
that destroys memory and thinking skills. Currently, there are no
drug therapies to halt Alzheimer’s disease, much less reverse its
course. In the U.S. alone, approximately 5.8 million people are
currently living with Alzheimer’s disease, and approximately
487,000 people age 65 or older developed Alzheimer’s in 2019. The
number of people living with Alzheimer’s disease is expected to
grow dramatically in the years ahead, resulting in a growing social
and economic burden.
About
SimufilamSimufilam is Cassava Sciences’ lead
therapeutic product candidate for the treatment of Alzheimer’s
disease. Simufilam is a proprietary, small molecule (oral) drug
that restores the normal shape and function of altered filamin A
(FLNA), a scaffolding protein, in the brain. Altered FLNA in the
brain disrupts the normal function of neurons, leading to
Alzheimer’s pathology, neurodegeneration and neuroinflammation. The
underlying science is published in peer-reviewed scientific
journals, including Journal of Neuroscience, Neurobiology of Aging,
Journal of Biological Chemistry, Neuroimmunology and
Neuroinflammation and Journal of Prevention of Alzheimer’s
Disease.
About Cassava Sciences,
Inc.Cassava Sciences’ mission is to discover and develop
innovations for chronic, neurodegenerative conditions. Over the
past 10 years, Cassava Sciences has combined state-of-the-art
technology with new insights in neurobiology to develop novel
solutions for Alzheimer’s disease. For more information, please
visit: https://www.CassavaSciences.com
For More Information
Contact:Eric Schoen, Chief Financial OfficerCassava
Sciences, Inc.eschoen@CassavaSciences.com(512) 501-2450
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Sep 2023 to Sep 2024